An interventional study of Active tDCS and Sham tDCS in Cognitive Deficit, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by University of Michigan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 148 studies in Cognition Disorders with a site in United States — 21 open to participants now, 27 under way, none of them phase 3. Cognition Disorders · United States.
Among the 148 studies in Cognition Disorders with a site in United States, this one is the 7th largest by planned enrollment of the 114 interventional ones that give a count, is one of 11 that started in 2016, is one of 56 with no phase, reaches primary completion later than 15 of the 26 other live ones, and was the 99th registered.
399 studies on the registry are indexed under Cognition Disorders; 72 are open to participants now.
Browse Cognition Disorders studies →21 of the 148 studies in Cognition Disorders with a site in United States are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Japan, Korea, Republic of and 1 more country
Ages 55–85
The Neurology Center of Southern California · Sites in United States
Ages 18–100 · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 60–85
Hebrew SeniorLife · Sites in United States, Israel
Ages 65–90
Massachusetts General Hospital · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Cognition Disorders studies recruiting now, 20 (43%) set no upper age limit and 11 (24%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
148 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 31 · Phase 3 12 · Phase 4 11
First in 1988; this study’s year is marked. 11 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 66 across 272 interventional studies indexed under Cognition Disorders.
Median enrollment 72 across the 114 interventional studies, 230 across the 31 observational. Of the 112 that completed or were terminated, 33 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 148 have an industry lead sponsor. The 10 most frequent:
University of Michigan is the lead sponsor of 1,509 studies on the registry; 194 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 134 (79%) have results posted.
University of Michigan has 1 study filed under Cognition Disorders — fewer than ten, so there is no comparison to draw.
6 of the studies in Cognition Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05802680Francisco Gonzalez-Lima, PhDNeurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation | 2026-12-31 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT05617014University of Southern CaliforniaAlzheimer's Disease Neuroimaging Initiative 4 | 2027-07-31 |
| NCT05201534Stanford UniversityInterventions in Mathematics and Cognitive Skills | 2027-08-31 |
| NCT03036319University of MichiganPatient-Centered NeuroRehabilitation (PCN) | 2027-11 |
Add all 6 to your calendar (.ics) → With an account.
Among the 148 studies in Cognition Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
As individuals grow older, a number of factors can reduce our cognitive (or thinking) abilities such as "normal" aging, neurodegenerative diseases, and cardiovascular disease. This study will evaluate whether cognitive rehabilitation and transcranial electrical stimulation (TES) can improve cognitive abilities. Cognitive rehabilitation refers to methods that are used to improve tasks people have trouble doing in everyday life. Transcranial electrical stimulation uses small amounts of electricity to try to alter brain functioning. These approaches may help improve cognitive abilities like attention, learning, memory, finding words, and problem solving as well as everyday functioning. The goal of this study is to identify how to best use these methods, either alone or in combination.
The primary objective of this study is to evaluate the feasibility of a neurorehabilitation treatment tailored to individual patient needs, with the ultimate goal of maximizing cognitive and real-world functioning for older adults with cognitive aging, mild cognitive impairment (MCI), neurodegenerative, or other neurological diseases/conditions.
Transcranial electrical stimulation (TES) is a non-invasive, neurorehabilitation procedure in which a weak electric current is passed between electrodes that are placed on the scalp with the intention of modulating excitability of the underlying brain regions. Because the field of TES is relatively young, rapidly evolving, and primarily focused on cognitive neuroscience with "healthy" individuals, there is a clear need for well-conceptualized and conducted clinical research. The current protocol is intentionally broad with respect to both methodology and patient characteristics in order to tailor potential TES interventions to individual patients or small samples. The current protocol utilizes various forms of TES including transcranial direct current stimulation (tDCS), alternating current stimulation (tACS), and random noise stimulation (tRNS) and sham stimulation in older adults. As this is a cross-over design, some participants may receive active (or "real") TES and/or sham TES conditions.This includes head to head comparisons of the different forms of TES. Additionally, TES could be performed in conjunction with cognitively-based intervention since this may enhance the neuroplastic response of the targeted brain region(s) while at the same time shaping/optimizing the pathways that are engaged by cognitively-based interventions. This broad approach is important since etiological differences in cognitive impairment may necessitate distinct interventions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Those who are being evaluated for TES methodology will also be excluded for 1) metallic or electronic implant 2) skull plates or other cranial implants that affect TES
Participants will receive "real" tES (tDCS, tACS, tRNS) in which they receive up to 4 milliamps (mA) of stimulation per electrode for up to 40 minutes for up to 260 sessions. As this may be a cross-over design, some participants may receive active and sham conditions.
Device: Active tDCS · Device: Active tACS · Device: Active tRNS
Participants undergoing this condition will have the exact same procedures as the active group, with the exception that they will receive only sham stimulation for up to 260 sessions.
Device: Sham tDCS · Device: Sham tACS · Device: Sham tRNS
Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation.
Behavioral: Cognitively based intervention
This condition combines active TES and cognitively based interventions for some or all of the study sessions
Device: Active tDCS · Behavioral: Cognitively based intervention · Device: Active tACS · Device: Active tRNS
This condition combines sham TES and cognitively based interventions for some or all of the study sessions
Device: Sham tDCS · Behavioral: Cognitively based intervention · Device: Sham tACS · Device: Sham tRNS
This condition combines active and sham TES with cognitively based interventions using a cross-over design
Device: Active tDCS · Device: Sham tDCS · Behavioral: Cognitively based intervention · Device: Active tACS · Device: Sham tACS · Device: Active tRNS · Device: Sham tRNS
Participants will receive active and sham TES
Device: Active tDCS · Device: Sham tDCS · Device: Active tACS · Device: Sham tACS · Device: Active tRNS · Device: Sham tRNS
Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.
Participants will receive sham tDCS for up to 260 sessions
Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
Participants will receive sham transcranial random noise stimulation for up to 260 sessions
TES side effect questionnaire
Side effect questionnaire that asks participants to rate the severity of potential TES related side effects
Time frame: Immediately following TES (<15 minutes)
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jun 2016, a primary completion of Nov 2027 and a completion of Nov 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.